Exicure (NASDAQ:XCUR) Stock Price Down 4.5% - Here's Why

Exicure, Inc. (NASDAQ:XCUR - Get Free Report) shares fell 4.5% on Monday . The company traded as low as $9.77 and last traded at $10.04. 4,221 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 574,559 shares. The stock had previously closed at $10.51.

Exicure Trading Up 0.5%

The stock's fifty day moving average price is $11.16 and its two-hundred day moving average price is $12.62. The firm has a market capitalization of $61.73 million, a price-to-earnings ratio of -4.72 and a beta of 3.86.

Exicure (NASDAQ:XCUR - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

Institutional Investors Weigh In On Exicure

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC acquired a new stake in Exicure, Inc. (NASDAQ:XCUR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,645 shares of the company's stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure at the end of the most recent quarter. 42.82% of the stock is currently owned by institutional investors and hedge funds.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.